北美最先进的抗衰老医疗技术,打造由内至外的抗衰老疗程

以下症状困扰您吗?

  • 肥胖:
    BMI超过25,或是脂肪都集中在肚子
  • 免疫力低下:
    经常感冒,发烧,易受寒
  • 伤口愈合能力低
  • 荷尔蒙失调:
    忧郁不安、心悸失眠、易惊醒、表情淡漠,易疲劳、记忆力衰退、阵发性潮热、精神过敏
  • 长期疲劳,体力不佳,四肢乏力
  • 睡眠不好问题
  • 身体疼痛:
    头疼,肌肉疼痛,关节疼痛
  • 头痛,头晕,耳鸣
  • 痛风
  • 记忆力与集中力不佳
  • 生活压力高
  • 老化速度过快
  • 性能力降低

或是您希望提升身体机能,做好抗衰老保养,

血液治疗,可能帮助您找回健康与青春。


适合血液氧化治疗疗法的疾病非常多:

  • 心脑血管疾病:冠心病,動脈硬化,高血压,高血脂,高胆固醇,中风等。
  • 糖尿病
  • 痛风
  • 病毒感染:乙肝,丙肝,流感,爱滋等。
  • 细菌感染:肺炎,莱姆病,心内膜炎,肠胃炎,泌尿道发炎等。
  • 真菌感染:念珠球菌感染,机会感染性疾病。
  • 免疫性疾病:多发性硬化,类风湿性关节炎,系统性红斑狼疮
  • 老化与退化性疾病:退化性关节炎,老年痴呆等。
  • 各种癌症


治疗机制:

1. 对抗感染性疾病(细菌,病毒,真菌感染):

体外血液氧化治疗能够破坏细菌细胞壁,干扰病毒与正常细胞的连结与复制,破坏病毒衣壳,抑制真菌/霉菌生长周期,杀死癌细胞,使健康细胞取代生病细胞,刺激体内氧气代谢系统非常安全且无任何副作用。

2. 对心脑血管疾病(冠心病,缺血性心脏病,高血压,高血脂):

世界卫生组织WHO每年都会做死亡统计:第一死因一直是心脑血管疾病,第二位是癌症。体外血液氧化治疗对于心脑血管疾病治疗效果卓越,能够溶解血管壁内的脂肪囤积,疏通血管,降低血中低密度脂蛋白与甘油三酯,使血液中携氧量增加。不只可以预防,而且还能治疗各种心血管疾病。另外,對於缺血性或是再灌注性心律不整也有相当大的帮助。

(动脉硬化示意图)

3. 对抗痛风:

早期体外血液氧化治疗多用于治疗癌症与降低癌症病患的疼痛,但是无意中发现,可以有效降低癌症患者体内尿酸数值。于是,便有很多临床试验相继出现:经临床证实四至五次治疗后再连续观察七个月,在无任何药物辅助下,疼痛度(pain VAS scores)可降低最高达86%,肌酐清除率最多增高137%,并且降低体内炎症反应。

 

4. 对抗二型糖尿病:

二型糖尿病除了对胰岛素不敏感的问题外,还有三磷酸腺苷(ATP)数量降低与能量生成障碍等问题。体外血液氧化治疗可以刺激体内2,3-二磷酸甘油酸(2,3-DPG)的生成,提高红细胞糖酵解速度,增高血红素携氧量并且可以更有效释放至体内各器官,增加体内含氧量,增加身体代谢率。除此之外,体外血液过滤高氧化治疗还促进丙酮酸的氧化脱羧,激活更多体内三羧酸循環,可促进生成更多ATP。提高人体对于食物的能量利用与代谢,体现为血糖水平的有效控制与胰岛素敏感度的提升。以上几点可以有效控制与治疗糖尿病。

糖尿病的并发症分为微血管型(由于小血管受损)和大血管型(由于大血管受损)。微血管并发症包括:眼睛受损(视网膜病变),可能导致失明;肾脏受损(肾病),导致肾衰竭;以及神经受损(神经病变),导致阳痿和糖尿病足(包括可能导致截肢的严重感染)。大血管并发症包括心血管疾病,比如心脏病发作、中风以及腿部血流不足。通过大型随机对照试验得来的证据显示,对一型和二型糖尿病进行良好的代谢控制可延缓这类并发症的发生和发展。对于糖尿病并发症,使用体外血液过滤高氧化治疗也可以得到控制:改善末稍循环,提升愈合能力,控制感染,避免血管病变。

5. 对抗癌症:

癌症是种复杂的疾病,造成癌症的因素有许多,从遗传基因,体内高重金属和化学污染,到生活习惯等都有可能导致癌症发生。血液治疗除了可以有效杀死癌细胞外,另外可以用来治疗化疗与物疗中造成的副作用,也可以减少癌症疼痛度。

6. 对抗免疫性疾病:

体外血液氧化治疗可以激活人体免疫机能,可以大大增加体内循环干扰素(interferon),提高肿瘤坏死因子(tumor necrosis factor)与白細胞介素-2(interleukin-2)的产生,诱导体内各种免疫连锁反应,大幅增加身体免疫力。

7. 对抗身体衰老:

体外血液氧化治疗可以减少自由基对人体的伤害,刺激人体抗老化系统的运作。前面提到了这治疗能够有效增加细胞ATP,ATP是细胞存亡的关键,维持细胞的完整性,ATP的增加代表細胞能够生存更久。高氧化的血液还可以替换掉生病或不良的细胞(这类细胞的细胞壁酶不完整,容易被侵入,造成疾病),让健康的新细胞取而代之。另外,体外血液过滤高氧化治疗能够有效降低NADH,并且帮助氧化細胞色素C,刺激身体新生细胞保护酶类与自由基清除酶类:谷胱甘肽过氧化物酶, 过氧化氢酶(CAT),与超氧化物歧化酶(SOD)。

总结体外血液氧化治疗:

  1. 抗老化,减少自由基伤害
  2. 增加细胞内的含氧量,帮助身体各器官运作
  3. 调节免疫系统,适用各种免疫性疾病
  4. 增加胰岛素敏感度,平衡血糖,改善二型糖尿病
  5. 减少体内尿酸,增加肌酐清除率
  6. 增加细胞的能量生成
  7. 使体内环境偏碱性
  8. 有效杀死破坏细胞的细菌,病毒,真菌
  9. 杀死癌细胞,可用于治疗癌症

如何进行治疗:

首先,柯医生会帮您做详细问诊,开立需要化验的项目,然后规划整体抗衰老治疗。抗衰老治疗是个整体性治疗,包括多项治疗来达到最佳效果。体外血液氧化治疗是种走静脉的治疗,抽出血液后,经过氧化与处理再输送回体内来达到治疗效果。全程无痛,部分身体较差的患者容易出现恶心或头晕等症状,属于正常赫克斯海默尔反应 (Herxheimer reaction: 当体内病原体突然大量死亡,释放出类似毒素的产物,刺激免疫系统过度反应的现象),待身体排出有害物质后便会恢复正常。

整个治疗过程约1~2小时。

治疗次数与频率根据个体而有所不同,治疗前需要医生详细问诊与化验,通常需要1~10次不等的治疗,每周一至两次,建议每半年做一次疗程来维持身体健康。

体外血液氧化治疗颠覆所有抗衰老治疗,是最先进的德国医疗技术,能够輔助治疗各类疾病。欢迎谘询。

 

——————————————————

Referenceså:

1. Di Paolo N, Bocci V, Gaggioti E. Ozone therapy editorial review. Int J Artificial Organs. 2004;27:168–75. [PubMed]

2. Bocci V. Biological and clinical effects of ozone: Has ozone therapy a future in medicine? Br J Biomed Sci. 1999;56:270–9. [PubMed]

3. Bocci V. Does ozone therapy normalize the cellular redox balance? Implications for the therapy of human immunodeficiency virus infection and several other diseases. Med Hypothesis. 1996;46:150–4.[PubMed]

4. Razumovskii, Zaikov . New York: Elsevier; 1984. Ozone and its reactions with organic compounds. Available from: http://ozonicsint.com/articles_vivo.html .

5. Health and Environmental Effects of Ground-Level Ozone. U.S. EPA. 1997. Jul, Available from:http://www.practicalasthma.net/pages/topics/aaozone.htm .

6. Folinsbee LJ. Effects of ozone exposure on lung function in man. Rev Environ Health. 1981;3:211–40.[PubMed]

7. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol. 2006;16:493–504. [PubMed]

8. Holmes J. Clinical reversal of root caries using ozone, double-blind, randomised, controlled 18-month trial. Gerodontology. 2003;20:106–14. [PubMed]

9. Hernández F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radical Biol Med. 1995;19:115–9. [PubMed]

10. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, et al. Effect of ozone therapy on muscle oxygenation. J Altern Complement Med. 2003;9:251–6. [PubMed]

11. Shoemaker JM. Ozone therapy: History, physiology, indications, results. [cited in 2010]. Available from: http://www.fullcircleequine.com/oz_therapy.pdf .

12. McLean L. The miracle of ozone therapy. [cited in 2009 Jun]. Available from:http://www.zeusinfoservice.com/Articles/TheMiracleofOzoneTherapy.pdf .

13. Stoker G. Ozone in chronic middle ear deafness. Lancet. 1902;160:1187–8.

14. Wells KH, Latino J, Gavalchin J, Poiesz BJ. Inactivation of human immunodeficiency virus type 1 by ozone in vitro. Blood. 1991;78:1882–90. [PubMed]

15. Carpendale MT, Freeberg JK. Ozone inactivates HIV at noncytotoxic concentrations. Antiviral Res. 1991;16:281–92. [PubMed]

16. Haug KF, Heidelberg, Rilling S, Viebahn R. The use of Ozone in Medicine, classical medical ozone textbook. 11 edition 1987. 

17. Sunnen GV. Ozone in medicine: Overview and future directions. J Adv Med. 1988;1:159–74.

18. Washutti J, Viebahn R, Steiner I. The influence of ozone on tumor tissue in comparison with healthy tissue. Ozone Sci Engg. 1990;12:65–72.

19. Washutti J, Viebahn R, Steiner I. Immunological examinations in patients with chronic conditions under administration of ozone/oxygen mixtures. Ozone Sci Engg. 1989;11:411–7.

20. Zänker KS, Kroczek R. In vitro synergistic activity of 5-fluorouracil with low-dose ozone against a chemoresistant tumor cell line and fresh human tumor cells. Int J Exp Clin Chemother. 1990;36:147–54.[PubMed]

21. Bocci V, Paulesu L. Studies on the biological effects of ozone 1: Induction of interferon on human leucocytes. Haematologica. 1990;75:510–15. [PubMed]

22. Viebahn-Hansler R. Ozone therapy-the underlying therapeutical concept and models of efficacy. Erfahrungs Heilkunde. 1991;4:40.

23. Kawalski H, Sondej J, Cierpiol TE. The use of ozonotherapy in nose correction operations. Acta Chirurgiae Plasticae. 1992;34:182–4. [PubMed]

24. Johnson AS, Ferrara JJ, Steinberg SM. Irrigation of the abdominal cavity in the treatment of experimentally induced microbial peritonitis: efficacy of ozonated saline. Am Surg J. 1993;59:297–303.[PubMed]

25. Gérard V, Sunnen MD. SARS and ozone therapy: Theoretical considerations. [cited in 2003]. Available from: http://www.triroc.com/sunnen/topics/sars.html .

26. Why consider ozone therapy/oxygen Spa as alternative treatment dallas fort worth? [cited in 2010]. Available from: http://www.holisticbodyworker.com/ozone_therapy_documentation.html .

27. Viebahn-Hänsler R. The use of ozone in medicine: Mechanisms of action. Munich. 2003. May 23-25, [cited in 2003]. Available from: http://www.oxidation-therapy.com/pdfs/MechanismofAction.pdf .

28. Bimosiamose: An Antiinflammatory Glycomimetic. [cited in 2010]; available from:http://www.revotar.de/pdf/BioTOPics24_Bock.pdf .

29. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, Wolff G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther. 2006;19:233–41. [PubMed]

30. Study to evaluate the effect of bimosiamose on ozone induced sputum neutrophilia. [cited in 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00962481 .

31. Evaluate the effects of the drug (SB-656933-AAA) on the body after a single dose in subjects who have inhaled ozone. [cited in 2010]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00551811.

32. Intraarticular ozone therapy for pain control in osteoarthritis of the knee. [cited in 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00832312?term=ozone+therapyandrank=2 .

33. The Effect of Ozone Therapy for Lumbar Herniated Disc. [cited in 2010]. Available from:http://clinicaltrials.gov/ct2/show/NCT00566007?term=ozone+therapyandrank=1 .

34. Andreula CF, Simonetti L, De Santis F, Agati R, Ricci R, Leonardi M. Minimally invasive oxygen-ozone therapy for lumbar disk herniation. AJNR Am J Neuroradiol. 2003;24:996–1000. [PubMed]

35. D’Erme M, Scarchilli A, Artale AM. Ozone therapy in lumbar sciatic pain. Radiol Med. 1998;95:21–4.[PubMed]

36. Hazucha MJ, Bates DV, Bromberg PA. Mechanism of action of ozone on the human lung. J Appl Physiol. 1989;67:1535–41. [PubMed]

37. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, Re L, Giuliani A, Candelario-Jalil E, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol. 2005;523:151–61. [PubMed]

38. Carpendale MT, Freeberg JK. Ozone inactivates HIV at noncytotoxic concentrations. Anitiviral Res. 1991;16:281–92. [PubMed]

39. Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies: A hypothesis. Med Hypothesis. 1992;39:30–4. [PubMed]

40. Sharma M, Hudson JB. Ozone gas is an effective and practical antibacterial agent. Am J Infect Control. 2008;36:559–63. [PubMed]

41. Di Filippo C, Cervone C, Rossi C, di Ronza C, Marfella R, Capodanno P, et al. Antiarrhythmic effect of acute oxygen-ozone administration to rats. Eur J Pharmacol. 2010;629:89–95. [PubMed]

42. Pryor WA, Squadrito GL, Friedman M. A new mechanism for the toxicity of ozone. Toxicol Lett. 1995;82-83:287–93. [PubMed]

43. Pryor WA, Squadrito GL, Friedman M. The cascade mechanism to explain ozone toxicity: The role of lipid ozonation products. Free Radical Biol Med. 1995;19:935–41. [PubMed]

44. Donovan DH, Williams SJ, Charles JM, Menzel DB. Ozone toxicity: Effect of dietary vitamin E and polyunsaturated fatty acids. Toxicol Lett. 1977;1:135–9.

45. Mustafa MG. Biochemical basis of ozone toxicity. Free Radical Biol Med. 1990;9:245–65. [PubMed]

46. Roycroft JH, Gunter WB, Menzel DB. Ozone toxicity: Hormone-like oxidation products from arachidonic acid by ozone-catalyzed autoxidation. Toxicol Lett. 1977;1:75–82.

47. Johansson E, Claesson R, van Dijken JW. Antibacterial effect of ozone on cariogenic bacterial species. J Dent. 2009;37:449–53. [PubMed]

48. Fuccio C, Luongo C, Capodanno P, Giordano C, Scafuro MA, Siniscalco D, et al. A single subcutaneous injection of ozone prevents allodynia and decreases the over-expression of pro-inflammatory caspases in the orbito-frontal cortex of neuropathic mice. Eur J Pharmacol. 2008;603:42–9. [PubMed]

49. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582–1587. [PubMed]

50. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–447. [PubMed]

51. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination on Survey III, 1988–1994. Am J Kidney Dis. 2002;40:37–42. [PubMed]

52. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470–1476. [PubMed]

53. Smith EU, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24:811–827. [PubMed]

54. Miao Z, Li C, Chen Y, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859–1864.[PubMed]

55. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii2–ii8. [PubMed]

56. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443–449. [PubMed]

57. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1988;41:778–799. [PubMed]

58. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. [PubMed]

59. Kim SY, De Vera MA, Choi HK. Gout and mortality. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S115–S119. [PubMed]

60. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15 Suppl):S435–S442. [PubMed]

61. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–2406. [PubMed]

62. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35. [PMC free article][PubMed]

63. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drug Aging. 2007;24:21–36. [PubMed]

64. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11:1795–1804. [PubMed]

65. White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep. 2007;9:36–43.[PubMed]

66. Soleimani M. Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. Acta Physiol (Oxf) 2011;201:55–62. [PubMed]

67. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–163. [PubMed]

68. Chernyshev AL, Filimonov RM, Karasev AV, et al. Combined treatment including ozonotherapy of patients with viral hepatitis. Vopr Kurortol Fizioter Lech Fiz Kult. 2008;3:19–22. (In Russian) [PubMed]

69. De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med. 2005;11:363–367. [PubMed]

70. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009;29:646–682. [PubMed]

71. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol. 2011;47:185–190. [PubMed]

72. Zhang W, Doherty M, Pascual E, Bardin T, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1301–1311. [PMC free article] [PubMed]

73. Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm. 2004;13:3–11. [PMC free article] [PubMed]

74. Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents. 1998;12:67–75. [PubMed]

75. Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. IV Interaction of monosodium urate crystals with dogfish and human leukocytes. Arthritis Rheum. 1975;18:153–165.[PubMed]

76. Kozin F, Ginsberg MH, Skosey JL. Polymorphonuclear leukocyte responses to monosodium urate crystals: modification by adsorbed serum proteins. J Rheumatol. 1979;6:519–526. [PubMed]

77. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218–227. [PubMed]

78. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-23. [PubMed]

79. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003;111:431-3. [PMC free article] [PubMed]

80. Pecorelli A, Bocci V, Acquaviva A, et al. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol 2013;267:30-40. [PubMed]

81. Bocci V, Valacchi G. Free radicals and antioxidants: how to reestablish redox homeostasis in chronic diseases? Curr Med Chem 2013;20:3397-415. [PubMed]

82. Bocci V, Zanardi I, Huijberts MS, et al. An integrated medical treatment for type-2 diabetes. Diabetes Metab Syndr 2014;8:57-61. [PubMed]

error: Content is protected !!